RespireRx Pharmaceuticals Inc (fka RSPI)

[Market_Fest4]

I'm just saying that what he says is no big deal. Of course one would call into question the Ampakine platform after an FDA rejection. I did it myself.

My conclusion is that the FDA psych division are a bunch of cowards and took the easy way out. Unfortunately, I believe that whatever ampakine is submitted for widespread use will be excessively scrutinized. Almost all drugs have minor side effects (like an erection lasting more than 4 hours), but the FDA lets them go to market. I believe if a BP sponsored the Ampakine, the FDA would be more constructive.

As such, I think CORs best path would be getting something approved for an acute condition. Once an ampakine is available (and a revenue stream), then COR or a BP partner can try to expand into a mass market indication. I think Stoll realizes this too and will say so in a CC.
MF4